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Abstract 
Review on NTSR1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: NTR 
HGNC (Hugo): NTSR1 
Location: 20q13.33 
Note 
Neurotensin receptor 1 is the high affinity receptor 
for neurotensin, a 13 amino acid peptide with 
neurotransmitter and hormone functions. 
Neurotensin binds 3 known receptors. Two of them 
belong to the superfamily of G-protein coupled 
receptors (GPCR): NTSR1 the high affinity 
receptor for neurotensin and NTSR2 its low affinity 
receptor, both belonging to GPCR class A (Mazella 
et al., 1996). The third receptor is NTR3 or sortilin, 
a member of VPS10 family (Petersen et al., 1997; 
Mazella et al., 1998).  
NTSR1 through neurotensin binding is implicated 
in several functions, the modulation of 
dopaminergic systems, analgesia, and inhibition of 
food uptake, hypothermia, hypotension, intestinal 
motility and digestive secretions. 
DNA/RNA 
Description 
The length of NTSR1 gene is 53.93 Kb, including 4 
exons and 3 introns. 
Transcription 
Two transcripts are identified, a 4132 bp coding for 
a protein of 418 aa. The second contains 2950 bp 
but without yet identified coding protein. 
Protein 
Description 
NTSR1 (418 aa in human) belongs to the GPCR 
family containing 7 TM domains. Its structure 
contains 4 extracellular and intracellular loops, the 
N terminal amino acid extracellular part located in 
extra cellular region.  
Four glycosylation sites (extracellular) are reported 
as essential for the functions. The binding of 
neurotensin is depending on 6 aa of the 4th 
extracellular loop of the protein (Vincent et al., 
1999). 
Expression 
In central nervous system, NTSR1 is expressed in 
substantia nigra, ventral tegmental area, amygdal 
nucleus, striatum and entorrhinal and prefrontal 
cortices (Kanba at al., 1986; Nicot et al., 1994).  
In extra cerebral region, NTSR1 was detected in 
small intestine (Seybold et al., 1990; Mendez et al., 
1997), fundus of stomach (Huidobro-Toro et al., 
1985), pancreas (Wang et al., 2000), fetal liver 
(Ehrenfried et al., 1994), colon (Mendez et al., 
1997) uterine tissue (Rodriguez et al., 2010) and 
prostate (Swift et al., 2010). 
NTSR1 expression in human cells was reported in 
prostatic cells (Swift et al., 2010), colonic epithelial 
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cells (Martin et al., 2002), lymphocytes (Evers et 
al., 1994) including T (Magazin et al., 2004) and B 
lymphocytes (Saada et al., 2012). 
Localisation 
In the cell membrane: Activation of NTSR1 
through neurotensin binding needs some post 
translational events including glycosylation and 
palmitoylation to downstream heterotrimeric G 
protein subunits effectors. This lipidation allows its 
localization within cell membrane microdomains 
and enhances the interaction with Gαq /11 which 
mainly reside within structured microdomains. This 
NTSR-1-mediated MAPK signaling and cellular 
proliferation was demonstrated in breast cancer 
cells (Heakal et al., 2011).  
Endocytosis: After activation by neurotensin, 
NTSR1 is desensitized through its internalization in 
endosomal vesicles in association with β-arrestin. 
This event requires phosphorylation depending on 
the C terminal region of NTSR1. Intracellular 
trafficking leads to NTSR1 degradation in 
lysosomes (Mazella and Vincent, 2006). 
Function 
NTSR1 is activated by neurotensin binding through 
autocrine or paracrine mechanism. Several 
signalizations were described depending on cell 
lines. 
Indeed, neurotensin induces Erk phosphorylation 
colonic HT29 cells through PLC activation leading 
to Inositol phosphate formation (Massa et al., 
2011). 
The recruitment of G protein was described through 
NTSR1 activation in microdomains (Heakal et al., 
2011).  
In other cell types, cell proliferation, migration and 
invasion are depending on a transactivation of 
EGFR by NTSR1 (Amorino et al., 2007; Moody et 
al., 2014 ) or act through the increase of expression 
and activation of EGFR, HER2, HER3 (Younes et 
al., 2014; Dupouy et al., 2014). 
Homology 
The NTSR1 gene is conserved in Rhesus monkey, 
dog, cow, mouse, rat, chicken, zebrafish, and frog. 
81 organisms have orthologs with human gene 
NTSR1. 
Conservation during evolution: 
NTSR1 gene is retrieved in jaw vertebrates 
(Gnathostomes) from the australian ghostshark, 
(Callorhinchus milii) to man, including most 
vertebrate groups (Teleosts, Coelacanth, the 
Amphibian Rana catesbeiana (Hwang et al., 2009), 
reptiles (python and lizard), birds and mammals. 
The duplication giving rise to NTSR1 and NTSR2 
occurred probably in early vertebrates via the 
genome doubling (R2) events but details are  
unknown, as genes clearly encoding neurotensin 
receptors are doubtfully present in more basal 
vertebrates such as lampreys and hagfishes.  
Unlike its paralogue gene, NTSR1 was subject to 
positive selection in mammals, as numerous genes 




NTSR1 is associated with the tumor grade and is a 
candidate risk factor involved in ductal breast 
cancer progression (Dupouy et al., 2009). Its 
functions in oncogenesis depend on EGFR, HER2 
and HER3 expression in breast cancer cells 
(Dupouy et al., 2014). 
Lung cancer 
NTSR1 is overexpressed in lung cancer (Alifano et 
al., 2010b).  
Its activation enhances HER2, HER3 and EGFR 
expression in lung cancer (Younes et al., 2014). 
Pharmacological NTSR1 inhibitor (SR48692) 
inhibits EGFR activation (Moody et al., 2014). 
Malignant pleural mesothelioma 
In malignant pleural mesothelioma, neurotensin and 
NTSR1 are significantly overexpressed in patients 
(Alifano et al., 2010a). 
Head and neck squamous cell 
carcinomas 
NTSR1 contributed to cancer cell invasion and 
migration and is highly expressed in patients with 
metastasis (Shimizu et al., 2008). 
Prostatic cancer 
NTSR1 is overexpressed in malignant prostatic 
tumors and malignant cell lines (Swift et al., 2010). 
Pancreatic cancer 
An increase of NTSR1 expression is detected in 
human ductal pancreatic adenocarcinoma (Reubi et 
al., 1998; Wang et al., 2000) as well as in PANC-1 
cell line (Wang et al., 2011). 
Colorectal cancer 
NTSR1 is associated with human cell proliferation 
(Massa et al., 2011), promotes tumor development 
in mouse colon cancer model (Bugni et al., 2012) 
and is overexpressed in colorectal cancer 
progression (Gui et al., 2008).  
NTSR1 activates miR-21 and miR-155, via Akt and 
NFkB, to down-regulate PTEN and SOCS1 and 
promote growth of tumors in mice.  
NTR1, miR-21, and miR-155 levels are increased 
in human colon tumor samples and correlate with 
tumor stage (Bakirtzi et al., 2011). 
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Glioblastoma 
Neurotensin through NTSR1 activation is 
implicated in maintaining glioblastoma stem, 
depending on IL-8 and Stat3 pathways (Zhou et al., 
2014). 
Melanoma 
SR48692 through NTSR1 inhibition decreases 
melanoma cell proliferation and induces melanoma 
cell apoptosis (Zhang et al., 2014). 
Neurodegenerative and psychiatric 
diseases 
Schizophrenia and Parkinson disease (Ferraro et al., 
2014) and addiction (Ma et al., 2013). 
Inflammation 
NTSR1 is overexpressed in colonic epithelial cells 
during inflammatory bowel diseases (Castagliuolo 
et al., 1999; Gui et al., 2013) 
References 
Alifano M, Loi M, Camilleri-Broet S, Dupouy S, Régnard 
JF, Forgez P. Neurotensin expression and outcome of 
malignant pleural mesothelioma. Biochimie. 2010 
Feb;92(2):164-70 
Alifano M, Souazé F, Dupouy S, Camilleri-Broët S, Younes 
M, Ahmed-Zaïd SM, Takahashi T, Cancellieri A, Damiani 
S, Boaron M, Broët P, Miller LD, Gespach C, Regnard JF, 
Forgez P. Neurotensin receptor 1 determines the outcome 
of non-small cell lung cancer. Clin Cancer Res. 2010 Sep 
1;16(17):4401-10 
Amorino GP, Deeble PD, Parsons SJ. Neurotensin 
stimulates mitogenesis of prostate cancer cells through a 
novel c-Src/Stat5b pathway. Oncogene. 2007 Feb 
1;26(5):745-56 
Bakirtzi K, Hatziapostolou M, Karagiannides I, Polytarchou 
C, Jaeger S, Iliopoulos D, Pothoulakis C. Neurotensin 
signaling activates microRNAs-21 and -155 and Akt, 
promotes tumor growth in mice, and is increased in human 
colon tumors. Gastroenterology. 2011 Nov;141(5):1749-
61.e1 
Bugni JM, Rabadi LA, Jubbal K, Karagiannides I, Lawson 
G, Pothoulakis C. The neurotensin receptor-1 promotes 
tumor development in a sporadic but not an inflammation-
associated mouse model of colon cancer. Int J Cancer. 
2012 Apr 15;130(8):1798-805 
Castagliuolo I, Wang CC, Valenick L, Pasha A, Nikulasson 
S, Carraway RE, Pothoulakis C. Neurotensin is a 
proinflammatory neuropeptide in colonic inflammation. J 
Clin Invest. 1999 Mar;103(6):843-9 
Dupouy S, Viardot-Foucault V, Alifano M, Souazé F, Plu-
Bureau G, Chaouat M, Lavaur A, Hugol D, Gespach C, 
Gompel A, Forgez P. The neurotensin receptor-1 pathway 
contributes to human ductal breast cancer progression. 
PLoS One. 2009;4(1):e4223 
Ehrenfried JA, Zhou Z, Thompson JC, Evers BM. 
Expression of the neurotensin gene in fetal human liver 
and fibrolamellar carcinoma. Ann Surg. 1994 
Oct;220(4):484-9; discussion 489-91 
Evers BM, Bold RJ, Ehrenfried JA, Li J, Townsend CM Jr, 
Klimpel GR. Characterization of functional neurotensin 
receptors on human lymphocytes. Surgery. 1994 
Aug;116(2):134-9; discussion 139-40 
Ferraro L, Beggiato S, Borroto-Escuela DO, Ravani L, 
O'Connor WT, Tomasini MC, Borelli AC, Agnati LF, 
Antonelli T, Tanganelli S, Fuxe K. Neurotensin NTS1-
dopamine D2 receptor-receptor interactions in putative 
receptor heteromers: relevance for Parkinson's disease 
and schizophrenia. Curr Protein Pept Sci. 2014;15(7):681-
90 
Gromova P, Rubin BP, Thys A, Erneux C, Vanderwinden 
JM. Neurotensin receptor 1 is expressed in gastrointestinal 
stromal tumors but not in interstitial cells of Cajal. PLoS 
One. 2011 Feb 18;6(2):e14710 
Gui X, Guzman G, Dobner PR, Kadkol SS. Increased 
neurotensin receptor-1 expression during progression of 
colonic adenocarcinoma. Peptides. 2008 Sep;29(9):1609-
15 
Hagihara A, Miyamoto K, Furuta J, Hiraoka N, Wakazono 
K, Seki S, Fukushima S, Tsao MS, Sugimura T, Ushijima 
T. Identification of 27 5' CpG islands aberrantly methylated 
and 13 genes silenced in human pancreatic cancers. 
Oncogene. 2004 Nov 11;23(53):8705-10 
Heakal Y, Woll MP, Fox T, Seaton K, Levenson R, Kester 
M. Neurotensin receptor-1 inducible palmitoylation is 
required for efficient receptor-mediated mitogenic-signaling 
within structured membrane microdomains. Cancer Biol 
Ther. 2011 Sep 1;12(5):427-35 
Huidobro-Toro JP, Kullak A. Excitatory neurotensin 
receptors on the smooth muscle of the rat fundus: possible 
implications in gastric motility. Br J Pharmacol. 1985 
Apr;84(4):897-910 
Hwang JI, Kim DK, Kwon HB, Vaudry H, Seong JY. 
Phylogenetic history, pharmacological features, and signal 
transduction of neurotensin receptors in vertebrates. Ann 
N Y Acad Sci. 2009 Apr;1163:169-78 
Kanba KS, Kanba S, Okazaki H, Richelson E. Binding of 
[3H]neurotensin in human brain: properties and 
distribution. J Neurochem. 1986 Mar;46(3):946-52 
Kosiol C, Vinar T, da Fonseca RR, Hubisz MJ, Bustamante 
CD, Nielsen R, Siepel A. Patterns of positive selection in 
six Mammalian genomes. PLoS Genet. 2008 Aug 
1;4(8):e1000144 
Ma H, Huang Y, Zhang B, Wang Y, Zhao H, Du H, Cong Z, 
Li J, Zhu G. Association between neurotensin receptor 1 
gene polymorphisms and alcohol dependence in a male 
Han Chinese population. J Mol Neurosci. 2013 
Oct;51(2):408-15 
Magazin M, Poszepczynska-Guigné E, Bagot M, Boumsell 
L, Pruvost C, Chalon P, Culouscou JM, Ferrara P, 
Bensussan A. Sezary syndrome cells unlike normal 
circulating T lymphocytes fail to migrate following 
engagement of NT1 receptor. J Invest Dermatol. 2004 
Jan;122(1):111-8 
Martin S, Navarro V, Vincent JP, Mazella J. Neurotensin 
receptor-1 and -3 complex modulates the cellular signaling 
of neurotensin in the HT29 cell line. Gastroenterology. 
2002 Oct;123(4):1135-43 
Massa F, Tormo A, Béraud-Dufour S, Coppola T, Mazella 
J. Neurotensin-induced Erk1/2 phosphorylation and growth 
of human colonic cancer cells are independent from 
growth factors receptors activation. Biochem Biophys Res 
Commun. 2011 Oct 14;414(1):118-22 
Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, 
Vincent JP. Structure, functional expression, and cerebral 






Atlas Genet Cytogenet Oncol Haematol. 2015; 19(10) 620 
 
localization of the levocabastine-sensitive 
neurotensin/neuromedin N receptor from mouse brain. J 
Neurosci. 1996 Sep 15;16(18):5613-20 
Mazella J, Vincent JP. Internalization and recycling 
properties of neurotensin receptors. Peptides. 2006 
Oct;27(10):2488-92 
Mazella J, Zsürger N, Navarro V, Chabry J, Kaghad M, 
Caput D, Ferrara P, Vita N, Gully D, Maffrand JP, Vincent 
JP. The 100-kDa neurotensin receptor is gp95/sortilin, a 
non-G-protein-coupled receptor. J Biol Chem. 1998 Oct 
9;273(41):26273-6 
Méndez M, Souazé F, Nagano M, Kelly PA, Rostène W, 
Forgez P. High affinity neurotensin receptor mRNA 
distribution in rat brain and peripheral tissues. Analysis by 
quantitative RT-PCR. J Mol Neurosci. 1997 Oct;9(2):93-
102 
Moody TW, Chan DC, Mantey SA, Moreno P, Jensen RT. 
SR48692 inhibits non-small cell lung cancer proliferation in 
an EGF receptor-dependent manner. Life Sci. 2014 Mar 
28;100(1):25-34 
Nicot A, Rostene W, Berod A. Neurotensin receptor 
expression in the rat forebrain and midbrain: a combined 
analysis by in situ hybridization and receptor 
autoradiography. J Comp Neurol. 1994 Mar 15;341(3):407-
19 
Petersen CM, Nielsen MS, Nykjaer A, Jacobsen L, 
Tommerup N, Rasmussen HH, Roigaard H, Gliemann J, 
Madsen P, Moestrup SK. Molecular identification of a 
novel candidate sorting receptor purified from human brain 
by receptor-associated protein affinity chromatography. J 
Biol Chem. 1997 Feb 7;272(6):3599-605 
Politopoulos I, Gibson J, Tapper W, Ennis S, Eccles D, 
Collins A. Genome-wide association of breast cancer: 
composite likelihood with imputed genotypes. Eur J Hum 
Genet. 2011 Feb;19(2):194-9 
Ramez M, Bagot M, Nikolova M, Boumsell L, Vita N, 
Chalon P, Caput D, Ferrara P, Bensussan A. Functional 
characterization of neurotensin receptors in human 
cutaneous T cell lymphoma malignant lymphocytes. J 
Invest Dermatol. 2001 Sep;117(3):687-93 
Reubi JC, Waser B, Friess H, Büchler M, Laissue J. 
Neurotensin receptors: a new marker for human ductal 
pancreatic adenocarcinoma. Gut. 1998 Apr;42(4):546-50 
Rodríguez Y, Almeida TA, Valladares F, Báez D, Montes 
de Oca F, García C, Dorta I, Hernández M, Reyes R, Bello 
AR. Neurotensin and neurotensin receptor 1 expression in 
human myometrium and uterine leiomyomas. Biol Reprod. 
2010 Oct;83(4):641-7 
Saada S, Marget P, Fauchais AL, Lise MC, Chemin G, 
Sindou P, Martel C, Delpy L, Vidal E, Jaccard A, Troutaud 
D, Lalloué F, Jauberteau MO. Differential expression of  
neurotensin and specific receptors, NTSR1 and NTSR2, in 
normal and malignant human B lymphocytes. J Immunol. 
2012 Dec 1;189(11):5293-303 
Seybold VS, Treder BG, Aanonsen LM, Parsons A, Brown 
DR. Neurotensin binding sites in porcine jejunum: 
biochemical characterization and intramural localization. 
Synapse. 1990;6(1):81-90 
Shimizu S, Tsukada J, Sugimoto T, Kikkawa N, Sasaki K, 
Chazono H, Hanazawa T, Okamoto Y, Seki N. 
Identification of a novel therapeutic target for head and 
neck squamous cell carcinomas: a role for the 
neurotensin-neurotensin receptor 1 oncogenic signaling 
pathway. Int J Cancer. 2008 Oct 15;123(8):1816-23 
Swift SL, Burns JE, Maitland NJ. Altered expression of 
neurotensin receptors is associated with the differentiation 
state of prostate cancer. Cancer Res. 2010 Jan 
1;70(1):347-56 
Vincent JP, Mazella J, Kitabgi P. Neurotensin and 
neurotensin receptors. Trends Pharmacol Sci. 1999 
Jul;20(7):302-9 
Wang JG, Li NN, Li HN, Cui L, Wang P. Pancreatic cancer 
bears overexpression of neurotensin and neurotensin 
receptor subtype-1 and SR 48692 counteracts neurotensin 
induced cell proliferation in human pancreatic ductal 
carcinoma cell line PANC-1. Neuropeptides. 2011 
Apr;45(2):151-6 
Wang L, Friess H, Zhu Z, Graber H, Zimmermann A, Korc 
M, Reubi JC, Büchler MW. Neurotensin receptor-1 mRNA 
analysis in normal pancreas and pancreatic disease. Clin 
Cancer Res. 2000 Feb;6(2):566-71 
Younes M, Wu Z, Dupouy S, Lupo AM, Mourra N, 
Takahashi T, Fléjou JF, Trédaniel J, Régnard JF, Damotte 
D, Alifano M, Forgez P. Neurotensin (NTS) and its receptor 
(NTSR1) causes EGFR, HER2 and HER3 over-expression 
and their autocrine/paracrine activation in lung tumors, 
confirming responsiveness to erlotinib. Oncotarget. 2014 
Sep 30;5(18):8252-69 
Zhang Y, Zhu S, Yi L, Liu Y, Cui H. Neurotensin receptor1 
antagonist SR48692 reduces proliferation by inducing 
apoptosis and cell cycle arrest in melanoma cells. Mol Cell 
Biochem. 2014 Apr;389(1-2):1-8 
Zhou J, Yi L, Ouyang Q, Xu L, Cui H, Xu M. Neurotensin 
signaling regulates stem-like traits of glioblastoma stem 
cells through activation of IL-8/CXCR1/STAT3 pathway. 
Cell Signal. 2014 Dec;26(12):2896-902 
This article should be referenced as such: 
Saada S, Marget P, Abacci A, Fauchais AL, Jauberteau 
MO, Petit D, Lalloue F. NTSR1 (neurotensin receptor 1 
(high affinity)). Atlas Genet Cytogenet Oncol Haematol. 
2015; 19(10):617-620. 
